Replies to post #106008 on Biotech Values

[mcbio]

I would say they should charge a minimum of 250k a year with benefit like this. why are they even going into phase 3?
* AMG 386 extends survival 1.6 mos vs chemotherapy alone

Come on drbio, because a 2-month survival advantage could easily support 500k/year. Seriously though, the PR says the Phase 3 will test AMG 386 + paclitaxel. It looks like this Phase 2 may have only been AMG 386 compared to paclitaxel, though I can't tell for sure from the PR. So, perhaps there could be better results when combining AMG 386 with paclitaxel. If the Phase 3 is the same protocol as the Phase 2, then I'd agree it's probably a waste.